Shares in Sun Pharmaceuticals Industries and Ranbaxy Laboratories are trading higher by up to 5% as UBS raised the rating on these stocks to ‘Buy’ after the acquisition deal.
Sun Pharma has rallied 5% to Rs 618 and Ranbaxy Laboratories is up 3% at Rs 459 on the National Stock Exchange (NSE).
Sun Pharma on Monday announced that it will acquire 100% of Ranbaxy Laboratories in a $4 billion all-share transaction.
Both companies said that they had entered definitive agreements under which Ranbaxy shareholders will receive 0.8 shares of Sun Pharma for every share of Ranbaxy.
Meanwhile, according to an analyst at HDFC Securities, Sun's history of acquisitions has been the most promising among its Indian peers given the turnaround of Taro and the handling of persistent FDA issues at Caraco's plant. Hence, there is immense comfort in this buyout.
Being an all-stock transaction, incrementally, the deal will not drain the balance sheet of Sun but only dilute its equity by around 20%. Moreover, Ranbaxy has been valued at a mere 2.2x its CY13 sales and probably less than 1.0x its potential CY13 sales. This points to a huge potential to create value for the shareholders of both Sun as well as Ranbaxy over the next 2/3 years, said the analyst in a report.
Sun Pharma has rallied 5% to Rs 618 and Ranbaxy Laboratories is up 3% at Rs 459 on the National Stock Exchange (NSE).
Sun Pharma on Monday announced that it will acquire 100% of Ranbaxy Laboratories in a $4 billion all-share transaction.
Both companies said that they had entered definitive agreements under which Ranbaxy shareholders will receive 0.8 shares of Sun Pharma for every share of Ranbaxy.
Meanwhile, according to an analyst at HDFC Securities, Sun's history of acquisitions has been the most promising among its Indian peers given the turnaround of Taro and the handling of persistent FDA issues at Caraco's plant. Hence, there is immense comfort in this buyout.
Being an all-stock transaction, incrementally, the deal will not drain the balance sheet of Sun but only dilute its equity by around 20%. Moreover, Ranbaxy has been valued at a mere 2.2x its CY13 sales and probably less than 1.0x its potential CY13 sales. This points to a huge potential to create value for the shareholders of both Sun as well as Ranbaxy over the next 2/3 years, said the analyst in a report.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%